CN112807337B - 一种坎巴嘎布提取物及其制备方法和应用 - Google Patents
一种坎巴嘎布提取物及其制备方法和应用 Download PDFInfo
- Publication number
- CN112807337B CN112807337B CN202110264491.0A CN202110264491A CN112807337B CN 112807337 B CN112807337 B CN 112807337B CN 202110264491 A CN202110264491 A CN 202110264491A CN 112807337 B CN112807337 B CN 112807337B
- Authority
- CN
- China
- Prior art keywords
- extract
- solution
- ethyl acetate
- under reduced
- reduced pressure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000284 extract Substances 0.000 title claims abstract description 104
- 238000000605 extraction Methods 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 66
- 239000011347 resin Substances 0.000 claims abstract description 57
- 229920005989 resin Polymers 0.000 claims abstract description 57
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 55
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 48
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 33
- 238000001179 sorption measurement Methods 0.000 claims abstract description 32
- 239000003208 petroleum Substances 0.000 claims abstract description 27
- 230000003266 anti-allergic effect Effects 0.000 claims abstract description 14
- 239000002994 raw material Substances 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 10
- 239000002024 ethyl acetate extract Substances 0.000 claims description 50
- 239000008213 purified water Substances 0.000 claims description 34
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 24
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 22
- 239000000706 filtrate Substances 0.000 claims description 22
- 239000003463 adsorbent Substances 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 19
- 239000007788 liquid Substances 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 11
- 230000003544 deproteinization Effects 0.000 claims description 11
- 239000012259 ether extract Substances 0.000 claims description 11
- 238000001914 filtration Methods 0.000 claims description 11
- 238000011068 loading method Methods 0.000 claims description 11
- 238000010992 reflux Methods 0.000 claims description 11
- 238000011010 flushing procedure Methods 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims description 8
- 238000004042 decolorization Methods 0.000 claims description 7
- 238000005406 washing Methods 0.000 claims description 6
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 4
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 claims description 4
- 241000195663 Scenedesmus Species 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000003995 emulsifying agent Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003906 humectant Substances 0.000 claims description 2
- 235000007122 Scenedesmus obliquus Nutrition 0.000 claims 1
- 241000195662 Tetradesmus obliquus Species 0.000 claims 1
- 230000002421 anti-septic effect Effects 0.000 claims 1
- 239000012153 distilled water Substances 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 67
- 235000019441 ethanol Nutrition 0.000 description 16
- 241000196324 Embryophyta Species 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- -1 steroid compounds Chemical class 0.000 description 11
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 9
- 201000004624 Dermatitis Diseases 0.000 description 8
- 108010003272 Hyaluronate lyase Proteins 0.000 description 8
- 102000001974 Hyaluronidases Human genes 0.000 description 8
- 229960002773 hyaluronidase Drugs 0.000 description 8
- 239000003937 drug carrier Substances 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 5
- 239000002026 chloroform extract Substances 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 229960000541 cetyl alcohol Drugs 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 208000034158 bleeding Diseases 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 239000004744 fabric Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 241001201097 Artemisia vestita Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 description 2
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000000043 antiallergic agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229930004069 diterpene Natural products 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229910044991 metal oxide Inorganic materials 0.000 description 2
- 150000004706 metal oxides Chemical class 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 229950011392 sorbitan stearate Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- 150000003648 triterpenes Chemical class 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 235000003826 Artemisia Nutrition 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 244000030166 artemisia Species 0.000 description 1
- 235000009052 artemisia Nutrition 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940092738 beeswax Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 238000010364 biochemical engineering Methods 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- SHWNNYZBHZIQQV-UHFFFAOYSA-L calcium;disodium;2-[2-[bis(carboxylatomethyl)azaniumyl]ethyl-(carboxylatomethyl)azaniumyl]acetate Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-L 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 125000000567 diterpene group Chemical group 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- SYELZBGXAIXKHU-UHFFFAOYSA-N dodecyldimethylamine N-oxide Chemical compound CCCCCCCCCCCC[N+](C)(C)[O-] SYELZBGXAIXKHU-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 229940100524 ethylhexylglycerin Drugs 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical class OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940001607 sodium bisulfite Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 229940001474 sodium thiosulfate Drugs 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- FWFUWXVFYKCSQA-UHFFFAOYSA-M sodium;2-methyl-2-(prop-2-enoylamino)propane-1-sulfonate Chemical compound [Na+].[O-]S(=O)(=O)CC(C)(C)NC(=O)C=C FWFUWXVFYKCSQA-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229950004959 sorbitan oleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/35—Extraction with lipophilic solvents, e.g. Hexane or petrol ether
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Botany (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Birds (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种坎巴嘎布提取物及其制备方法和应用。该发明以植物坎巴嘎布为原料，含水乙醇作为溶剂进行提取，所得提取液经过减压浓缩得浸膏，浸膏用蒸馏水溶解以后，依次用石油醚、乙酸乙酯进行萃取，收集浓缩乙酸乙酯萃取部分，得萃取物，该萃取物经过D101大孔吸附树脂脱糖、脱蛋白、脱色以后，得到坎巴嘎布提取物。该方法获得的坎巴嘎布提取物能够在抗敏类护肤品领域得到应用。该方法具有提取工艺简洁，成本低，易操作等优点。
Description
技术领域
本发明属于生物化工技术领域，涉及一种坎巴嘎布提取物及其制备方法和应用。
背景技术：
随着人们生活方式和生活环境的改变，越来越多的人会在生活中出现皮肤过敏的症状。皮肤过敏是一种很常见的过敏形式，有20％的人有皮肤过敏现象。皮肤过敏又称为过敏性皮肤。过敏性皮肤的一大特点就是发痒。从医学角度讲皮肤过敏主要是指当皮肤受到各种刺激，导致皮肤出现红肿、发痒、脱皮及过敏性皮炎等皮肤过敏症状，刺激来源可包含化妆品、化学制剂、花粉、某些食品、污染的空气等等。目前针对皮肤过敏这一症状，社会上主流的治疗方法是使用抗过敏药物，但是，服用过敏药物不但存在不良反应的安全隐患，还可能对药物造成依赖，从而引发反复性慢性过敏。
为了修复皮肤的炎症，提供具有抗过敏效用的护肤品，本发明从天然植物原料坎巴嘎布中提取了具有较好抗敏功效的植物成分。坎巴嘎布，学名“毛莲蒿”(Artemisiavestita Wall.ex Bess.)，为菊科，蒿属，半灌木状草本或为小灌木状；主产于甘肃、青海、西藏等海拔2000-4000米的地区。坎巴嘎布植株有浓烈的香气，具有较高的药用价值，《宇妥本草》中记载坎巴嘎布具有消肿、治肉瘤、肠病的功效；《药名荟萃》中记载坎巴嘎布具有止血、消四肢肿胀功效；《蓝琉璃》中记载坎巴嘎布有利肾病和补品的作用；坎巴嘎布在藏医药里也是作为止血、消肿、清热的药物，用于治疗各种疾病引起的出血、四肢肿胀、外伤等疾病。国内外对坎巴嘎布提取物用于抗敏类护肤品方面的应用研究未见有专利文献报道。
发明内容：
为了解决上述问题，本发明提供一种坎巴嘎布提取物，该提取物具有抗敏作用。
本发明的另一个目的是提供上述坎巴嘎布提取物的制备方法。该方法操作简单、易于产业化；提取坎巴嘎布的收率高。
本发明的另个一目的是提供该上述坎巴嘎布提取物在制备抗敏药物中的应用。
本发明是通过下述技术方案实现的：
本发明的一种坎巴嘎布提取物是坎巴嘎布原料用含水乙醇提取，提取液浓缩成浸膏后，采用萃取法和层析法纯化得到的提取物。
所述含水乙醇浓度为50-95％。优选70％乙醇。
所述萃取法：浸膏用水复溶后，用有机溶剂萃取，收集萃取物即可。
所述有机溶剂为石油醚、乙酸乙酯、乙醚、氯仿中的一种或几种。优选本发明所述的有机溶剂为石油醚和乙酸乙酯依次使用。
所述萃取法中水与有机溶剂的用量相同。
所述层析法：将萃取物过大孔树脂层析柱，先用0-30％乙醇水溶液洗脱，弃去，再用50-95％乙醇溶液洗脱，收集洗脱液即可。优选，依次水、20％乙醇洗脱，弃去，再用70％乙醇洗脱，收集洗脱液。
所述大孔树脂型号包括但不限于AB-8、D101等；优选D101大孔树脂柱。坎巴嘎布提取物主要功效成分是甾体化合物和二萜、三萜类等萜类化合物，经过筛选发现D101大孔树脂柱对此类物质具有较好的富集且容易解吸附被洗脱下来。
本发明提供一种组合物，其包含坎巴嘎布提取物和一种或多种药学上可接受的赋形剂，诸如佐剂、稀释剂或载体。所述坎巴嘎布提取物用量0.1-99.9％。
本发明的提取物，在制成药剂时，单位剂量的药剂可含有本发明的药物活性物质0.1-1000mg，其余为药学上可接受的载体。药学上可接受的载体以重量计可以是制剂总重量的0.1-99.9％。优选所述的药学上可接受的载体以重量计可以是制剂总重量的40-70％。在制成药物制剂时可以制成任何可药用的剂型，这些剂型选自：片剂、糖衣片剂、薄膜衣片剂、肠溶衣片剂、胶囊剂、硬胶囊剂、软胶囊剂、口服液、口含剂、颗粒剂、丸剂、散剂、膏剂、丹剂、混悬剂、溶液剂、注射剂、栓剂、软膏剂、硬膏剂、霜剂、喷雾剂、贴剂。优选的是口服制剂形式，最佳优选的是片剂，胶囊剂，颗粒剂。
本发明的提取物，根据需要可以加入一些药物可接受的载体，可以采用制剂学常规技术制备该药物制剂，如将药物活性物质与药物可接受的载体混合。所述药物可接受的的载体选自：甘露醇、山梨醇、山梨酸或钾盐、焦亚硫酸钠、亚硫酸氢钠、硫代硫酸钠、盐酸半胱氨酸、巯基乙酸、蛋氨酸、维生素A、维生素C、维生素E、维生素D、氮酮、EDTA二钠、EDTA钙钠，一价碱金属的碳酸盐、醋酸盐、磷酸盐或其水溶液、盐酸、醋酸、硫酸、磷酸、氨基酸、氯化钠、氯化钾、乳酸钠、木糖醇、麦芽糖、葡萄糖、果糖、右旋糖苷、甘氨酸、淀粉、蔗糖、乳糖、甘露糖醇、硅衍生物、纤维素及其衍生物、藻酸盐、明胶、聚乙烯吡咯烷酮、甘油、丙二醇、乙醇、土温60-80、司班-80、蜂蜡、羊毛脂、液体石蜡、十六醇、没食子酸酯类、琼脂、三乙醇胺、碱性氨基酸、尿素、尿囊素、碳酸钙、碳酸氢钙、表面活性剂、聚乙二醇、环糊精、β－环糊精、磷脂类材料、高岭土、滑石粉、硬脂酸钙、硬脂酸镁等。优选所述的载体为微晶纤维素、乳糖、淀粉、羧甲基纤维素钠、低取代羟丙基纤维素、滑石粉中一种或以上。
本发明的提取物制成药学上可接受的剂型，不需要载体或辅料，直接将药物组合物制成相应剂型，优选本发明药物组合物粉末直接装入胶囊壳中制得胶囊剂。
本发明所述的坎巴嘎布提取物可以包括在下述制剂中：保湿剂，诸如甘油(glycerol)、丙三醇(glycerin)、聚乙二醇、海藻糖、甘油、矿脂(petrolatum)、石蜡油、透明质酸及其盐(例如钠盐和钾盐)、辛酸/羊脂酸甘油三酯等；和/或抗氧化剂，诸如维生素和谷胱甘肽；和/或pH调节剂，诸如酸、碱和pH缓冲剂。此外，可以包括以下物质：表面活性剂/乳化剂，诸如十六烷醇(鲸蜡醇)、脂肪酸(例如硬脂酸)、十二烷基硫酸钠(月桂基硫酸钠)、山梨聚糖酯(例如山梨聚糖硬脂酸酯、山梨聚糖油酸酯等)、单酰基甘油酯(诸如单硬脂酸甘油酯)、聚乙氧基化醇、聚乙烯醇、多元醇酯、聚氧乙烯烷基醚(例如聚氧乙烯山梨聚糖单油酸酯)、聚氧乙烯蓖麻油衍生物、乙氧基化脂肪酸酯、聚氧甘油酯、月桂基二甲基胺氧化物、胆汁盐(例如脱氧胆酸钠、胆酸钠)、磷脂、N,N-二甲基十二烷胺-N-氧化物、十六烷基三甲基溴化铵、泊洛沙姆、卵磷脂、固醇(例如胆固醇)、糖酯、聚山梨酯等；防腐剂，诸如苯氧基乙醇、乙基己基甘油等；和增稠剂，诸如牛磺酸丙烯酰基二甲基酯/VP共聚物。特别地，硬脂酸、单硬脂酸甘油酯、十六醇、山梨聚糖硬脂酸酯、鲸蜡醇、辛酸/羊脂酸甘油酯等可以特别包括在乳膏制剂中。
本发明的提取物组合物，其用量0.1-99.9％，其它辅料包括但不限于保湿剂、乳化剂、PH值调节剂、皮肤调理剂、防腐剂、水等。
进一步优选，坎巴嘎布提取物用量0.1-1.5％。
本发明的一种组合物，其包括重量百分比的羟乙基纤维素0.1-0.3％、坎巴嘎布提取物0.1-1.2％、1，2-戊二醇1-3％、对羟基苯乙酮0.1-0.5％、甘油2-7％、栅藻提取物0.1-0.5％、余量的水。
更进一步优选，本发明的一种组合物，其包括重量百分比的羟乙基纤维素0.2％、坎巴嘎布提取物0.8-1.2％、1，2-戊二醇2％、对羟基苯乙酮0.3％、甘油5％、栅藻提取物0.3％、余量的水。
本发明提供的一种坎巴嘎布提取物的制备方法，包括如下步骤:
(1)取植物原料，按照料液比1:4-8的比例加入50-95％乙醇溶液，在50-70℃的条件下回流提取2-5小时，过滤得到滤液；将滤液在50-70℃的条件下减压浓缩成浸膏；
(2)浸膏用8-12倍量的纯化水溶解，转入分液漏斗中，得复溶液；复溶液中加入等量的石油醚，振荡均匀，然后静置，待溶液分层；去除石油醚萃取液，在水层溶液中加入等量的乙酸乙酯，振荡均匀，然后静置，待溶液分层；收集乙酸乙酯萃取液，50-70℃条件下减压浓缩至浸膏状，得乙酸乙酯萃取物；乙酸乙酯萃取物加入纯化水溶解，得乙酸乙酯萃取物水溶液；
(3)按照乙酸乙酯萃取物：大孔吸附树脂＝1:30-50的比例，将乙酸乙酯萃取物上样到大孔吸附树脂层析柱中；缓慢加入大孔吸附树脂8-12倍体积的纯化水进行冲柱，达到脱糖、脱蛋白的目的；加入大孔吸附树脂8-12倍体积的10-30％乙醇水溶液进行冲柱，达到脱色的目的；再加入大孔吸附树脂8-12倍体积的50-95％乙醇水溶液进行冲柱，收集该部分洗脱液，减压浓缩至浸膏状，得到坎巴嘎布提取物。
进一步优选，一种坎巴嘎布提取物的制备方法，包括如下步骤:
(1)取植物原料，按照料液比1:6的比例加入70％乙醇溶液，在60℃的条件下回流提取3小时，过滤得到滤液；将滤液在60℃的条件下减压浓缩成浸膏；
(2)浸膏用10倍量的纯化水溶解，转入分液漏斗中，得复溶液；复溶液中加入等量的石油醚，振荡均匀，然后静置4小时，待溶液分层；去除石油醚萃取液，在水层溶液中加入等量的乙酸乙酯，振荡均匀，然后静置4小时，待溶液分层；收集乙酸乙酯萃取液，50℃条件下减压浓缩至浸膏状，得乙酸乙酯萃取物；乙酸乙酯萃取物加入纯化水溶解，得乙酸乙酯萃取物水溶液；
(3)按照乙酸乙酯萃取物：D101大孔吸附树脂＝1:40的比例，将乙酸乙酯萃取物上样到D101大孔吸附树脂层析柱中；缓慢加入大孔吸附树脂10倍体积的纯化水进行冲柱，达到脱糖、脱蛋白的目的；加入大孔吸附树脂10倍体积的20％乙醇水溶液进行冲柱，达到脱色的目的；再加入大孔吸附树脂10倍体积的70％乙醇水溶液进行冲柱，收集该部分洗脱液，减压浓缩至浸膏状，得到坎巴嘎布提取物。
上述步骤(2)中所述萃取过程中，先采用石油醚进行萃取，是为了将粗提取物中的一些小极性的成分萃取掉，减少后期乙酸乙酯萃取部分中的杂质含量。采用乙酸乙酯进行萃取，可以将甾体类成分和二萜、三萜等萜类等易溶于乙酸乙酯的成分从水溶液中萃取出来，达到和其他成分进行分离的目的。
本发明提供一种坎巴嘎布提取物在制备抗过敏药物中的用途。
有益效果
通过本发明提取方法得到的坎巴嘎布提取物具有较好的抗过敏舒缓效果，能够在抗敏类护肤品领域得到应用。该方法具有提取工艺简洁，收率高，成本低，易操作等优点。
具体实施方式
下面结合附图，对本发明的具体实施方式进行详细描述，但应当理解本发明的保护范围并不受具体实施方式的限制。
实施例1制备例
(1)取植物原料，按照料液比1:6的比例加入70％乙醇溶液，在60℃的条件下回流提取3小时，过滤得到滤液；将滤液在60℃的条件下减压浓缩成浸膏；
(2)浸膏用10倍量的纯化水溶解，转入分液漏斗中，得复溶液；复溶液中加入等量的石油醚，振荡均匀，然后静置4小时，待溶液分层；去除石油醚萃取液，在水层溶液中加入等量的乙酸乙酯，振荡均匀，然后静置4小时，待溶液分层；收集乙酸乙酯萃取液，50℃条件下减压浓缩至浸膏状，得乙酸乙酯萃取物；乙酸乙酯萃取物加入纯化水溶解，得乙酸乙酯萃取物水溶液；
(3)按照乙酸乙酯萃取物：D101大孔吸附树脂＝1:40的比例，将乙酸乙酯萃取物上样到D101大孔吸附树脂层析柱中；缓慢加入大孔吸附树脂10倍体积的纯化水进行冲柱，达到脱糖、脱蛋白的目的；加入大孔吸附树脂10倍体积的20％乙醇水溶液进行冲柱，达到脱色的目的；再加入大孔吸附树脂10倍体积的70％乙醇水溶液进行冲柱，收集该部分洗脱液，减压浓缩至浸膏状，得到坎巴嘎布提取物。
本发明的坎巴嘎布提取物的提取率为6.2％
实施例2制备例
(1)取植物原料，按照料液比1:4的比例加入50％乙醇溶液，在50℃的条件下回流提取2小时，过滤得到滤液；将滤液在50℃的条件下减压浓缩成浸膏；
(2)浸膏用8倍量的纯化水溶解，转入分液漏斗中，得复溶液；复溶液中加入等量的石油醚，振荡均匀，然后静置4小时，待溶液分层；去除石油醚萃取液，在水层溶液中加入等量的乙酸乙酯，振荡均匀，然后静置4小时，待溶液分层；收集乙酸乙酯萃取液，50℃条件下减压浓缩至浸膏状，得乙酸乙酯萃取物；乙酸乙酯萃取物加入纯化水溶解，得乙酸乙酯萃取物水溶液；
(3)按照乙酸乙酯萃取物：D101大孔吸附树脂＝1:30的比例，将乙酸乙酯萃取物上样到AB-8大孔吸附树脂层析柱中；缓慢加入大孔吸附树脂8倍体积的纯化水进行冲柱，达到脱糖、脱蛋白的目的；加入大孔吸附树脂8倍体积的10％乙醇水溶液进行冲柱，达到脱色的目的；再加入大孔吸附树脂8倍体积的50％乙醇水溶液进行冲柱，收集该部分洗脱液，减压浓缩至浸膏状，得到坎巴嘎布提取物。
本发明的坎巴嘎布提取物的提取率为5.3％。
实施例3制备例
(1)取植物原料，按照料液比1:8的比例加入95％乙醇溶液，在70℃的条件下回流提取5小时，过滤得到滤液；将滤液在70℃的条件下减压浓缩成浸膏；
(2)浸膏用12倍量的纯化水溶解，转入分液漏斗中，得复溶液；复溶液中加入等量的石油醚，振荡均匀，然后静置4小时，待溶液分层；去除石油醚萃取液，在水层溶液中加入等量的乙酸乙酯，振荡均匀，然后静置4小时，待溶液分层；收集乙酸乙酯萃取液，70℃条件下减压浓缩至浸膏状，得乙酸乙酯萃取物；乙酸乙酯萃取物加入纯化水溶解，得乙酸乙酯萃取物水溶液；
(3)按照乙酸乙酯萃取物：D101大孔吸附树脂＝1:50的比例，将乙酸乙酯萃取物上样到D101大孔吸附树脂层析柱中；缓慢加入大孔吸附树脂12倍体积的纯化水进行冲柱，达到脱糖、脱蛋白的目的；加入大孔吸附树脂12倍体积的30％乙醇水溶液进行冲柱，达到脱色的目的；再加入大孔吸附树脂12倍体积的95％乙醇水溶液进行冲柱，收集该部分洗脱液，减压浓缩至浸膏状，得到坎巴嘎布提取物。本发明的坎巴嘎布提取物的提取率为5.1％。
实施例4制备例
(1)取植物原料，按照料液比1:6的比例加入70％乙醇溶液，在60℃的条件下回流提取3小时，过滤得到滤液；将滤液在60℃的条件下减压浓缩成浸膏；
(2)浸膏用10倍量的纯化水溶解，转入分液漏斗中，得复溶液；复溶液中加入等量的石油醚，振荡均匀，然后静置4小时，待溶液分层；去除石油醚萃取液，在水层溶液中加入等量的乙酸乙酯，振荡均匀，然后静置4小时，待溶液分层；收集乙酸乙酯萃取液，50℃条件下减压浓缩至浸膏状，得乙酸乙酯萃取物；乙酸乙酯萃取物加入纯化水溶解，得乙酸乙酯萃取物水溶液；
(3)按照乙酸乙酯萃取物：AB-8大孔吸附树脂＝1:40的比例，将乙酸乙酯萃取物上样到D101大孔吸附树脂层析柱中；缓慢加入大孔吸附树脂10倍体积的纯化水进行冲柱，达到脱糖、脱蛋白的目的；加入大孔吸附树脂10倍体积的20％乙醇水溶液进行冲柱，达到脱色的目的；再加入大孔吸附树脂10倍体积的70％乙醇水溶液进行冲柱，收集该部分洗脱液，减压浓缩至浸膏状，得到坎巴嘎布提取物。
本发明的坎巴嘎布提取物的提取率为4.6％。
实施例5制备例
(1)取植物原料，按照料液比1:6的比例加入70％乙醇溶液，在60℃的条件下回流提取3小时，过滤得到滤液；将滤液在60℃的条件下减压浓缩成浸膏；
(2)浸膏用10倍量的纯化水溶解，转入分液漏斗中，得复溶液；复溶液中加入等量的石油醚，振荡均匀，然后静置4小时，待溶液分层；去除石油醚萃取液，在水层溶液中加入等量的氯仿，振荡均匀，然后静置4小时，待溶液分层；收集氯仿萃取液，50℃条件下减压浓缩至浸膏状，得氯仿萃取物；氯仿萃取物加入纯化水溶解，得氯仿酯萃取物水溶液；
(3)按照氯仿萃取物：D101大孔吸附树脂＝1:40的比例，将氯仿萃取物上样到D101大孔吸附树脂层析柱中；缓慢加入大孔吸附树脂10倍体积的纯化水进行冲柱，达到脱糖、脱蛋白的目的；加入大孔吸附树脂10倍体积的30％乙醇水溶液进行冲柱，达到脱色的目的；再加入大孔吸附树脂10倍体积的70％乙醇水溶液进行冲柱，收集该部分洗脱液，减压浓缩至浸膏状，得到坎巴嘎布提取物。
本发明的坎巴嘎布提取物的提取率为5.5％。
实施例：组合物
表1含有坎巴嘎布提取物组合物
试验例抗敏反应
透明质酸酶(Hyaluronidase，HAase)可降解透明质酸，研究表明透明质酸酶与过敏、炎症有强相关，当肌肤存在内热症状，如炎症时，会伴随透明质酸酶活性的升高。抗敏实验采用透明质酸酶体外抑制实验检测受试液抑制透明质酸酶的活性效果，以验证本发明抗过敏效果。以纯化水为空白组。
表2透明质酸酶抑制率
上述表2试验结果可以看出，实施例9和10的透明质酸酶抑制率最好，优选坎巴嘎布提取物用量0.8-1.2％，由于0.8％和1.2％抑制率相差不多，优选0.8％作为在组合物中的用量，具有显著的抗敏功效。
Claims (11)
1.一种坎巴嘎布提取物，其特征在于：是由如下步骤制备得到的：
（1）取植物原料，按照料液比1:4-8的比例加入50-95%乙醇溶液，在50-70℃的条件下回流提取2-5小时，过滤得到滤液；将滤液在50-70℃的条件下减压浓缩成浸膏；
（2）浸膏用8-12倍量的纯化水溶解，转入分液漏斗中，得复溶液；复溶液中加入等量的石油醚，振荡均匀，然后静置，待溶液分层；去除石油醚萃取液，在水层溶液中加入等量的乙酸乙酯，振荡均匀，然后静置，待溶液分层；收集乙酸乙酯萃取液，50-70℃条件下减压浓缩至浸膏状，得乙酸乙酯萃取物；乙酸乙酯萃取物加入纯化水溶解，得乙酸乙酯萃取物水溶液；
（3）按照乙酸乙酯萃取物：大孔吸附树脂=1:30-50的比例，将乙酸乙酯萃取物上样到大孔吸附树脂层析柱中；缓慢加入大孔吸附树脂8-12倍体积的纯化水进行冲柱，达到脱糖、脱蛋白的目的；加入大孔吸附树脂8-12倍体积的10-30%乙醇水溶液进行冲柱，达到脱色的目的；再加入大孔吸附树脂8-12倍体积的50-95%乙醇水溶液进行冲柱，收集该部分洗脱液，减压浓缩至浸膏状，得到坎巴嘎布提取物。
2.根据权利要求1所述的提取物，其特征在于：所述大孔树脂型号为AB-8或D101。
3.根据权利要求2所述的提取物，其特征在于：所述大孔树脂型号为D101。
4.根据权利要求1所述的坎巴嘎布提取物，其特征在于，是由如下步骤制备得到的：
（1）取植物原料，按照料液比1:6的比例加入70%乙醇溶液，在60℃的条件下回流提取3小时，过滤得到滤液；将滤液在60℃的条件下减压浓缩成浸膏；
（2）浸膏用10倍量的纯化水溶解，转入分液漏斗中，得复溶液；复溶液中加入等量的石油醚，振荡均匀，然后静置4小时，待溶液分层；去除石油醚萃取液，在水层溶液中加入等量的乙酸乙酯，振荡均匀，然后静置4小时，待溶液分层；收集乙酸乙酯萃取液，50℃条件下减压浓缩至浸膏状，得乙酸乙酯萃取物；乙酸乙酯萃取物加入纯化水溶解，得乙酸乙酯萃取物水溶液；
（3）按照乙酸乙酯萃取物：D101大孔吸附树脂=1:40的比例，将乙酸乙酯萃取物上样到D101大孔吸附树脂层析柱中；缓慢加入大孔吸附树脂10倍体积的纯化水进行冲柱，达到脱糖、脱蛋白的目的；加入大孔吸附树脂10倍体积的20%乙醇水溶液进行冲柱，达到脱色的目的；再加入大孔吸附树脂10倍体积的70%乙醇水溶液进行冲柱，收集该部分洗脱液，减压浓缩至浸膏状，得到坎巴嘎布提取物。
5.根据权利要求1所述的一种坎巴嘎布提取物的制备方法，包括如下步骤:
（1）取植物原料，按照料液比1:4-8的比例加入50-95%乙醇溶液，在50-70℃的条件下回流提取2-5小时，过滤得到滤液；将滤液在50-70℃的条件下减压浓缩成浸膏；
（2）浸膏用8-12倍量的纯化水溶解，转入分液漏斗中，得复溶液；复溶液中加入等量的石油醚，振荡均匀，然后静置，待溶液分层；去除石油醚萃取液，在水层溶液中加入等量的乙酸乙酯，振荡均匀，然后静置，待溶液分层；收集乙酸乙酯萃取液，50-70℃条件下减压浓缩至浸膏状，得乙酸乙酯萃取物；乙酸乙酯萃取物加入纯化水溶解，得乙酸乙酯萃取物水溶液；
（3）按照乙酸乙酯萃取物：大孔吸附树脂=1:30-50的比例，将乙酸乙酯萃取物上样到大孔吸附树脂层析柱中；缓慢加入大孔吸附树脂8-12倍体积的纯化水进行冲柱，达到脱糖、脱蛋白的目的；加入大孔吸附树脂8-12倍体积的10-30%乙醇水溶液进行冲柱，达到脱色的目的；再加入大孔吸附树脂8-12倍体积的50-95%乙醇水溶液进行冲柱，收集该部分洗脱液，减压浓缩至浸膏状，得到坎巴嘎布提取物。
6.根据权利要求5所述的一种坎巴嘎布提取物的制备方法，包括如下步骤:
（1）取植物原料，按照料液比1:6的比例加入70%乙醇溶液，在60℃的条件下回流提取3小时，过滤得到滤液；将滤液在60℃的条件下减压浓缩成浸膏；
（2）浸膏用10倍量的纯化水溶解，转入分液漏斗中，得复溶液；复溶液中加入等量的石油醚，振荡均匀，然后静置4小时，待溶液分层；去除石油醚萃取液，在水层溶液中加入等量的乙酸乙酯，振荡均匀，然后静置4小时，待溶液分层；收集乙酸乙酯萃取液，50℃条件下减压浓缩至浸膏状，得乙酸乙酯萃取物；乙酸乙酯萃取物加入纯化水溶解，得乙酸乙酯萃取物水溶液；
（3）按照乙酸乙酯萃取物：D101大孔吸附树脂=1:40的比例，将乙酸乙酯萃取物上样到D101大孔吸附树脂层析柱中；缓慢加入大孔吸附树脂10倍体积的纯化水进行冲柱，达到脱糖、脱蛋白的目的；加入大孔吸附树脂10倍体积的20%乙醇水溶液进行冲柱，达到脱色的目的；再加入大孔吸附树脂10倍体积的70%乙醇水溶液进行冲柱，收集该部分洗脱液，减压浓缩至浸膏状，得到坎巴嘎布提取物。
7.一种组合物，其特征在于：所述组合物由权利要求1-4任意一项所述的坎巴嘎布提取物和一种或多种药学上接受的赋形剂、佐剂、稀释剂或载体组成；所述坎巴嘎布提取物用量0.1-99.9%。
8.根据权利要求7所述的组合物，其特征在于：所述坎巴嘎布提取物用量0.1-1.5%，其赋形剂包括保湿剂、乳化剂、PH值调节剂、皮肤调理剂、防腐剂中几种。
9.根据权利要求7所述的一种组合物，其特征在于，其是由重量百分比的羟乙基纤维素0.1-0.3%、坎巴嘎布提取物0.1-1.2%、1，2-戊二醇1-3%、对羟基苯乙酮0.1-0.5%、甘油2-7%、栅藻提取物0.1-0.5%、余量的水组成。
10.根据权利要求8所述的一种组合物，其特征在于，其是由重量百分比的羟乙基纤维素0.2%、坎巴嘎布提取物0.8-1.2%、1，2-戊二醇 2%、对羟基苯乙酮0.3%、甘油5%、栅藻提取物0.3%、余量的水组成。
11.如权利要求1-4任意一项所述的提取物或权利要求7-10任意一项所述的组合物在制备抗敏药物中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110264491.0A CN112807337B (zh) | 2021-03-11 | 2021-03-11 | 一种坎巴嘎布提取物及其制备方法和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110264491.0A CN112807337B (zh) | 2021-03-11 | 2021-03-11 | 一种坎巴嘎布提取物及其制备方法和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112807337A CN112807337A (zh) | 2021-05-18 |
| CN112807337B true CN112807337B (zh) | 2022-08-16 |
Family
ID=75863150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110264491.0A Expired - Fee Related CN112807337B (zh) | 2021-03-11 | 2021-03-11 | 一种坎巴嘎布提取物及其制备方法和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112807337B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114681500B (zh) * | 2022-03-14 | 2023-06-02 | 西藏藏医药大学 | 一种普尔那总黄酮提取物及其应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000198726A (ja) * | 1999-01-08 | 2000-07-18 | Mitsui Chemicals Inc | 過酸化脂質生成抑制剤及びこれを含有する組成物 |
| JP2001163759A (ja) * | 1999-12-10 | 2001-06-19 | Kose Corp | 美白剤及びそれを有効成分として含有する皮膚外用剤 |
| CN104762135A (zh) * | 2015-03-11 | 2015-07-08 | 罗利华 | 一种从大籽蒿或毛莲蒿中提取精油的方法 |
| CN110051616A (zh) * | 2019-06-13 | 2019-07-26 | 西藏圣雪生物科技有限公司 | 一种含坎巴嘎布提取物的洗护用品及其生产制备方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110496145B (zh) * | 2019-10-09 | 2022-12-09 | 中国科学院新疆理化技术研究所 | 一种大籽蒿有效部位的制备方法及其用途 |
-
2021
- 2021-03-11 CN CN202110264491.0A patent/CN112807337B/zh not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000198726A (ja) * | 1999-01-08 | 2000-07-18 | Mitsui Chemicals Inc | 過酸化脂質生成抑制剤及びこれを含有する組成物 |
| JP2001163759A (ja) * | 1999-12-10 | 2001-06-19 | Kose Corp | 美白剤及びそれを有効成分として含有する皮膚外用剤 |
| CN104762135A (zh) * | 2015-03-11 | 2015-07-08 | 罗利华 | 一种从大籽蒿或毛莲蒿中提取精油的方法 |
| CN110051616A (zh) * | 2019-06-13 | 2019-07-26 | 西藏圣雪生物科技有限公司 | 一种含坎巴嘎布提取物的洗护用品及其生产制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112807337A (zh) | 2021-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10967030B2 (en) | Traditional Chinese medicine composition for treating psoriasis and method for preparing the same | |
| CN104666373A (zh) | 东革阿里新用途 | |
| JP2009542634A (ja) | 絡石藤抽出物を含有する炎症性疾患の予防及び治療用医薬組成物 | |
| EP2910247B1 (en) | Compositions for preventing or treating allergic skin disorders, containing gpcr19 agents as active ingredients | |
| AU2021469614A1 (en) | Use of composition comprising astilbin and/or isomer thereof in preparation of drug for treating psoriasis | |
| CN112807337B (zh) | 一种坎巴嘎布提取物及其制备方法和应用 | |
| CN1970032B (zh) | 一种银翘败毒中药 | |
| CN114209739A (zh) | 一种白头翁提取物在制备治疗抗抑郁药物上的应用 | |
| CN103479688A (zh) | 一种治疗类风湿性关节炎的药物组合物其制备方法和用途 | |
| CN1565467B (zh) | 山茱萸及其提取物在制备α-葡萄糖苷酶抑制剂类药物中的用途 | |
| CN108314620B (zh) | 异序乌桕素i和j及其药物组合物和其应用 | |
| US9393277B2 (en) | Application of Albizzia chinensis extract in preparation of medicine for treatment of gastric ulcer | |
| CN102188483B (zh) | 一种治疗咽喉炎的提取物及其制备方法 | |
| KR102144566B1 (ko) | 택란 추출물을 유효성분으로 포함하는 아토피 피부염의 예방 또는 치료용 조성물 | |
| JP5649995B2 (ja) | セラミド産生促進剤 | |
| JP2005194239A (ja) | セラミド合成促進剤及び皮膚外用剤 | |
| KR20200079114A (ko) | 진세노사이드 Rg3을 포함하는 항염증 조성물 | |
| CN113861261B (zh) | 山绿茶三萜皂苷元类提取物、提取工艺、制剂及应用 | |
| JPH0717859A (ja) | アラキドン酸代謝異常疾患治療剤 | |
| KR20120057161A (ko) | 거북 추출물을 함유하는 피부질환의 개선 또는 치료용 약학적 조성물 | |
| CN106421077A (zh) | 一种高纯度文冠果总皂苷提取物的制备新方法及用途 | |
| KR101131108B1 (ko) | 도라지 막분리 추출물 또는 플라티코시드 ｅ를 유효성분으로 함유하는 아토피 피부염의 예방 또는 치료용 조성물 | |
| CN1327829C (zh) | 了哥王缓释制剂 | |
| CN101040905A (zh) | 用夏枯草制备的降血糖药物 | |
| JPH06172195A (ja) | Ｕｄｐ−グルクロニルトランスフェラーゼ阻害剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20220816 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |